TB-500 Safety for Young Adults (Ages 18 to 29): What the Evidence Actually Shows
HealthRX.com
Nothing is established about TB-500 safety in young adults
At a glance
- What it is / a synthetic 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4 [1]
- Human safety data / none found; FDA located no article giving TB-500 to a person [1]
- Data specific to ages 18 to 29 / none found [1]
- Approval status / not FDA-approved; no approved product in any country FDA checked [1]
- Established dose / none; no human dosing study [1]
- Published side effects / FDA found no published case reports [1]
- Sport / WADA prohibits thymosin beta-4 and its derivatives at all times [2]
- Compounding status / not on FDA's compounding bulks lists for state-licensed pharmacies, physicians or outsourcing facilities; the HHS policy is a non-binding draft [3][11][12][4]
Is TB-500 safe for young adults? What the evidence shows
The answer is unknown. FDA's July 2026 evaluation searched PubMed, Embase, ClinicalTrials.gov and other sources, and none of the three papers the nominator submitted involved TB-500 in humans [1]. There is no trial to break down by age and no adverse-event rate for a 22-year-old, or for anyone. The main safety concern FDA identified for the injectable form is immunogenicity, described below [1][5].
What people on Reddit report
These are self-reports from forum users, often using a blend of two research peptides for joint, tendon or muscle pain. None come from people in the young adult age group, and none are clinical data.
I know quite a few people over 65 who have experienced excellent results with these peptides at appropriate doses, with little or no side effects, certainly none of any significance. Most common issues are injection site irritation due to technique, or not maintaining sterility of the process.Read the source discussion
69 years here, had great success with no side effects. Left ankle pain completely gone with combo. I'm still an avid runner and play a lot of tennis.Read the source discussion
No negative side effects other than being out 180$, which was worth it for the Achilles and knee pain for sureRead the source discussion
Questions worth asking
What TB-500 is, and what it is not
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, residues 17 to 23, N-acetylated (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH), molecular weight about 889 g/mol, taken from a 43-amino-acid protein [1]. It is not full-length thymosin beta-4 and not thymosin alpha-1 [1]. 'TB-500' is a common name rather than an official drug name, and FDA found several salts and derivatives, including different active moieties, sold under it [1].
Human trials of thymosin beta-4 do not answer the TB-500 question
Most of the human data people cite comes from the full-length protein or from eye drops, not from TB-500.
- A phase 1 study gave 54 healthy volunteers a single intravenous dose of recombinant human thymosin beta-4 from 0.05 to 25 micrograms/kg; a further 30 volunteers received 0.5, 2 or 5 micrograms/kg daily for 10 days. Adverse events were mild to moderate, with no dose-limiting toxicity, no serious adverse events and no obvious accumulation [6].
- A phase 2 dry-eye trial randomised 72 adults to 0.1% thymosin beta-4 drops or placebo for 28 days. Neither primary endpoint differed significantly; several secondary endpoints did [7].
- A very small phase 2 trial in severe dry eye treated 9 patients, comparing 12 treated eyes with 6 vehicle eyes. At day 56, ocular discomfort was 35.1% lower and total corneal staining 59.1% lower than with vehicle [8].
- A randomised trial in 96 patients after a STEMI found a smaller infarct area at 90 days only in the subgroup given the first dose within 8 hours (n=43); the overall difference across all 96 was not significant [9].
None of these products was TB-500, so none of these results describes TB-500's safety or effect [1].
What laboratory and animal work shows
In an in-vitro scratch-wound test, TB-500 at 50 micrograms/mL did not induce wound closure in fibroblast cultures; a shorter metabolite, N-acetylated LKKTE, did show activity [1]. FDA found no in-vivo animal studies of TB-500 for wound healing [1].
Animal studies indicate that TB-500 given subcutaneously or intraperitoneally reaches the bloodstream and is broken down into smaller peptides; no animal studies by intramuscular injection were found, and there are no human pharmacokinetic or pharmacodynamic data by any route [1].
What FDA has flagged as the main risk
FDA's stated concern for injectable TB-500 is immunogenicity, an immune reaction, potentially amplified by peptide aggregation and peptide-related impurities [1][5]. FDA found no study of TB-500 immunogenicity or aggregation, and no nonclinical toxicity studies [1]. TB-500 sits in the 'nominated but withdrawn' table of FDA's safety-risk page, which lists substances previously in category 2 whose nominators withdrew them; that removal was not a finding that the substance is safe [5]. Likewise, no human or nonclinical toxicity data establish how TB-500 affects reproduction [1].
One human account connected to TB-500 appears in FDA's review of a different peptide. A 40-year-old woman developed widespread skin hyperpigmentation and gum darkening within a week of using a 'research purposes only' product containing BPC-157 5 mg plus TB-500 5 mg, injected subcutaneously twice daily; the reaction recurred when she tried the product again two weeks later. The product held two peptides, and FDA said it cannot tell whether either caused the reaction [10].
Reporting databases are thin. FDA's adverse-event database search through 26 March 2025 retrieved no TB-500 reports, and its food and supplement complaint system (1 January 2004 to 10 March 2025) returned two cases about a blended TB-500 and BPC-157 product with no safety assessment [1].
Approval and legal status
- TB-500 is not an FDA-approved drug. FDA's July 2026 review found no USP or National Formulary monograph, no FDA-approved drug containing it, no listing in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorised by the European Medicines Agency [1].
- It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) or on FDA's list for outsourcing facilities (updated 21 March 2025). FDA's category 1 policy does not cover it [11][12][3].
- FDA staff proposed that TB-500 not be added to the pharmacy bulks list, citing, among other reasons, no human data and no evidence of effectiveness for wound healing. FDA's Pharmacy Compounding Advisory Committee reviewed TB-500 on 23 July 2026 and voted in favour of adding it. That vote is advice only and not binding, and TB-500 is not on the list [1][13].
- HHS filed a draft enforcement-discretion policy on 28 October 2026 naming TB-500 among six peptides and covering the acetate form for subcutaneous or intramuscular injection. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met. The notice states that it does not establish rights for any person and is not binding on HHS or the public [4][14].
- Neither step is an approval, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [4].
On supply: TB-500 is sold online as a 'research use only' injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
Sport: prohibited at all times
WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, growth factors and growth factor modulators. It is prohibited at all times, in and out of competition, as a non-Specified Substance, and it appears on the 2026 List as well as the tracked-changes version of the 2027 List [2][15]. Anti-doping laboratories have worked on detection: WADA approved a 2013 project on TB-500 metabolite detection limits, and a 2012 paper described the synthesis and characterisation of the N-acetylated 17 to 23 fragment identified in TB-500 [1][16].
Is there a dose a young adult would take?
No dose has been established in humans: there is no approved dose and no human dosing study of TB-500 [1]. The nomination FDA reviewed proposed a 3 mg/mL lyophilised powder for subcutaneous or intramuscular injection, which is a proposal rather than a tested regimen [1]. Doses used in trials of recombinant full-length thymosin beta-4 are doses of a different product and do not apply to TB-500 [1].
Frequently asked questions
Is TB-500 safe for an 18- to 29-year-old?
Is there a standard TB-500 dose?
Can TB-500 be legally compounded in the United States?
Will TB-500 show up on an anti-doping test?
Is TB-500 the same as thymosin beta-4?
What side effects have been reported with TB-500?
References
Show all 19 referencesHide references
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-6.
- Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8.
- Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-20.
- Reddit participants. BPC 157 & TB500 side effect for 65 yrs old. (r/Biohackers). Accessed 2026-11-11.
- Reddit participants. Thoughts on BPC-157? (r/crossfit). Accessed 2026-11-11.